Elevated serum levels of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, at diagnosis may be useful as a prognostic marker of survival in ALS.
Why this matters
ALS is a progressive neurodegenerative disease, leading to death in a median time of 3 years after onset. However, prognosis of the disease is highly variable, ranging from a few months to over 30 years. Use of sNfL as biological marker to predict prognosis will help physicians to more accurately inform patients of their survival prognosis, and to better evaluate clinical trial outcomes.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.